10-year long-term survival of a metastatic EGFR-mutated nonsmall cell lung cancer patient

Eur Respir J. 2015 Jul;46(1):280-2. doi: 10.1183/09031936.00017315. Epub 2015 Apr 16.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage
  • Antineoplastic Agents / administration & dosage
  • Carcinoma, Non-Small-Cell Lung / genetics*
  • Carcinoma, Non-Small-Cell Lung / mortality
  • Clinical Trials as Topic
  • Disease-Free Survival
  • ErbB Receptors / genetics*
  • Erlotinib Hydrochloride / administration & dosage
  • Exons
  • Female
  • Gefitinib
  • Gene Deletion
  • Humans
  • Lung Neoplasms / genetics*
  • Lung Neoplasms / mortality
  • Middle Aged
  • Mutation*
  • Neoplasm Metastasis
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Quinazolines / administration & dosage
  • Treatment Outcome

Substances

  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Quinazolines
  • Erlotinib Hydrochloride
  • EGFR protein, human
  • ErbB Receptors
  • Protein-Tyrosine Kinases
  • Gefitinib